基于结构的设计和合成强效和选择性的KRAS G12D抑制剂
Hengmiao Cheng1, Puhui Li1, Ping Chen1
1Erasca Inc., 3115 Merryfield Row, Suite 300, San Diego, California 92121, United States.
ACS medicinal chemistry letters
|October 18, 2023
概括
研究人员开发了一种新药,ERAS-5024,针对胰腺癌中常见的KRAS G12D突变. 这种强大的抑制剂在临床前研究中显示出有前途,减少瘤生长和扩散.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 在胰腺管腺癌 (PDAC) 中,KRAS G12D突变很普遍,代表了重要的治疗标.
- 向瘤性KRAS突变是癌症研究的一个关键领域.
研究的目的:
- 设计和合成针对KRAS G12D突变的新型,强效和选择性抑制剂.
- 在相关癌症模型中评估化合物ERAS-5024的临床前疗效.
主要方法:
- 基于结构的药物设计原则被用于识别潜在的抑制剂.
- 实验室试验 (例如,Cell-Titer Glo) 用于评估化合物的功效和对细胞增殖的影响.
- 进行了体内疗效研究,以评估瘤回归.
主要成果:
- 一系列强效和选择性的KRAS G12D抑制剂已成功设计和合成.
- 化合物ERAS-5024在抑制ERK1/2酸化和ASPC-1PDAC细胞中的细胞增殖方面表现出单位纳米分子功效.
- 在体内疗效研究中,ERAS-5024表现出显著的瘤回归.
结论:
- 发现ERAS-5024代表了针对KRAS G12D突变胰腺癌的重大进展.
- 埃拉斯-5024显示出作为PDAC治疗剂的潜力,并需要进一步的临床研究.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
05:54Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
8.6K
相关概念视频
Structure-Activity Relationships and Drug Design
735
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
735
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
G Protein-coupled Receptors
12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
